The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach

Pelvender Singh Gill,1 Ian S D Roberts,2 Lisa Browning,1 Ranmith Perera,2 Anne Y Warren,3 Freddie C Hamdy,4 Clare Verrill1

ABSTRACT
This article reviews previously described methods of fresh tissue sampling from radical prostatectomy specimens for research and describes a method used in Oxford which is simple, logical and cost effective. The method utilises a systematic zonal approach to tissue procurement in order to meet the increasing requirement for research samples with detailed morphological information such as zone of origin, tumour stage and Gleason grade.

The described method involves punch biopsy sampling from a 4mm thick transverse slice cut 8mm superior to the apex. 9 biopsies are taken from each specimen in the following zonal distribution: Mid anterior, right lateral, right peripheral zone lateral, right peripheral zone mid, left peripheral zone mid, left peripheral zone lateral, left lateral, left transition zone and right transition zone.

The method was validated by successfully sampling tumour in 7 out of 8 cases (88%). In 6 of the positive cases, tumour was present in more than 1 punch biopsy.

A logical systematic method of fresh tissue sampling from radical prostatectomy specimens is presented, which balances the need for accurate routine histopathological reporting with the requirement for increasingly complex research samples to be taken with attention to morphological details such as zone and stage.

INTRODUCTION
In an era of rapidly developing advances in the field of cancer biology and genetics, it is of paramount importance that research into prostate cancer keeps pace with that of other organ systems as it is the commonest cancer arising in men in the UK.1 Regrettably, this is not the case and many aspects of the basic mechanisms by which prostate cancer arises remain elusive, by contrast to other tissues where exciting developments have translated into new management options for patients. For example, in breast cancer clear molecular subgroups have been identified with distinct clinical outcomes.2 In the treatment of malignant melanoma, the discovery that 50% of cases have activating BRAF mutations has revolutionised treatment of metastatic melanoma, which can be targeted with BRAF inhibitors such as Vemurafenib, and this drug is showing unprecedented improvement in survival outcome.3

Four recently described the marked variation in genetic expression signatures between biopsy samples taken from different regions of renal cell carcinomas. In the prostate, it is now recognised that some are the best source of prostatic carcinoma for research as prostate biopsies provide only limited material, while transurethral resection of prostate chippings are fraught with logistical problems including diathermy artefact and the majority of cases being benign.

There is increasing interest in the heterogeneity within and between tumours, making detailed morphological assessment of key importance. Gerlinger et al4 recently described the marked variation in genetic expression signatures between biopsy samples from different regions of renal cell carcinomas. In the prostate, it is now recognised that there are biological and genetic differences between transition zone, peripheral zone and anterior predominant tumours.5 6

Many techniques for obtaining fresh tissue from radical prostatectomy specimens have been described in the literature, with usually either a whole slice being taken for research or tissue being harvested from a cut surface, by shave sections or punch biopsy.7 Some methods require specialised equipment developed locally in the research institutions, which are not widely available.8–10 Others involve disrupting slices and subsequently the capsule and margins of the prostate,11 12 thus compromising routine histopathological reporting. Some techniques can only be performed with macroscopically evident tumour11 13 14 and as a high proportion of prostate cancers are not visible at dissection, sampling needs to be systematic rather than dependent on finding a macroscopically visible lesion.15 Methods involving trucut needle biopsies taken through the capsule may not provide sufficient material for study.16 Other techniques involve removal of large amounts of tissue for research, some methods taking 40–50% of the prostate for research, tissue that is effectively lost from routine reporting.12 17

A simple method for systematic sampling of fresh radical prostatectomy specimens is presented in this paper, which strikes a balance between the need for uncompromised histological reporting to the standards of the RCPath guidelines18 and providing research samples with detailed morphological information such as zone, Gleason grade and tumour stage. The method is compared with previously described techniques for comparison.
DESCRIBED METHOD

Patients are consented for tissue harvesting for the ProMPT study (NRES reference 01/4/061). Patients with only one positive core in the diagnostic biopsy are excluded in order to reduce the chances of a negative radical prostatectomy specimen. Patients with a prostatic volume on ultrasound of <30 cc and >100 cc are excluded because of the hypertrophy associated with larger cases (distorting the specimen when freshly sliced) and the increased chance of a negative radical prostatectomy with small prostates.

Oxford Radcliffe Biobank staff and the biobanking pathologist are notified approximately 30 min prior to the prostate being removed from the patient. The basic kit is prepared (figure 1): standard laboratory knife, laboratory inks, cutting guide plate with 4 mm cutting height and 5 mm skin punch biopsy utensil (Meditech Systems Ltd, Dorset, UK).

The prostate is placed in a plastic bag on ice in the operating room and transferred to pathology. The prostate is orientated, photographed and the external fascia and connective tissues are examined together with identification of any capsular incisions.

The specimen is inked according to the protocol in Oxford (right half of prostate inked blue, left half black and a strip of yellow ink marking anterior). The specimen is weighed and measured in three dimensions and seminal vesicles and vasa are also measured.

Using a standard laboratory knife, the apex of the prostate is removed approximately 8 mm above the urethral apex (figure 2). The cut surface of the prostate is then placed immediately onto the cutting guide plate and a 4 mm transverse slice is cut (figures 3 and 4). Punch biopsies are then sampled from this slice (figure 5) in the following systematic order (figure 6) and are immediately snap frozen:

1. Mid anterior
2. Right lateral
3. Right peripheral zone lateral
4. Right peripheral zone mid
5. Left peripheral zone mid
6. Left peripheral zone lateral
7. Left lateral
8. Left transition zone
9. Right transition zone.

In addition to this set of standard biopsies, additional punch biopsies can be taken if required or if the prostate is large, and the position of these biopsies is marked on a sampling diagram.

Figure 1  The basic kit required for sampling, including cutting guide plate, scales, knife, cork board, punch biopsy and a ruler. This figure is only reproduced in colour in the online version.

Figure 2  The prostate is orientated and capsular defects noted. The specimen is photographed front and back for documentation. After applying standard orientation inks, for example, left = black, right = blue and a strip of yellow for anterior, the prostate is placed on its relatively flat posterior surface and the apex is amputated aiming to remove a cone of approximately 8 mm of apical tissue in a single smooth movement with the blade. This figure is only reproduced in colour in the online version.

Figure 3  On removal of the apex, the organ is placed on the cutting guide plate, the newly exposed cut surface flat against the surface of the plate. The time taken will affect tissue expansion and this should be minimised and completed within 2–3 min at most (usually a minute). This figure is only reproduced in colour in the online version.

Figure 4  A 4 mm single slice is taken using the cutting guide plate. This figure is only reproduced in colour in the online version.
Punch biopsies 1–7 are taken close to the capsule in order to maximise the chances of sampling tumour, but within the capsule to avoid compromising capsular morphology. Biopsies 2 and 7 are usually taken from the most anterior horns of the right and left peripheral zones if possible, but sometimes may be taken from the transition zone (depending on the individual prostate). The apical cone, sampled transverse slice and the rest of the prostate are then pinned to cork board, face down to minimise bulging. It is necessary to pin the capsule with care, drawing it down with pins to ensure it does not retract (figure 7). Punch biopsy holes are inked around their periphery to distinguish them from artefacts.

The prostate is then placed in formalin for fixation and subsequent routine histopathological cut up. After fixation, the sampled slice is embedded in its entirety as a whole mount (figure 8). The apical cone is sliced perpendicular to the cut surface. The main part of the prostate is sliced in complete transverse sections with the base cut as a cone and the seminal vesicles and vasa removed and embedded separately.

After routine histopathological reporting, a punch biopsy sampling table is completed, which records (from assessment of tissue around the perimeter of the biopsy site) benign/malignant tissue, punch biopsy site, Gleason pattern(s) and stage of the tumour. By entering this information onto our database, there is easy retrieval of biopsies with particular features. Any biopsies selected for research can have a frozen section cut later for absolute confirmation of tissue diagnosis.

VALIDATION OF THE METHOD

Eight cases were sampled to validate the method. There was a mean time from receipt of specimen to snap freezing of samples of 23.5 min. Tumour was banked in 7/8 cases (88%) (table 1).
This method utilises a systematic zonal sampling approach, sampling transitional zone, peripheral zone and anterior zone. There is increasing recognition that there are biological and genetic differences between tumours arising in different zones of the prostate. For example, there are higher rates of TMPRSS2-ERG gene fusion in peripheral zone tumours compared with transition zone tumours. Hence, morphological identification of the punch biopsy site is of paramount importance.

Wheeler and Lebovitz describe a radical prostatectomy sampling method in which the prostate is divided into two halves and then 10 samples are taken using a set protocol. Four of these are from the peripheral zone, although they are taken as two mirror image pairs, effectively meaning they are only sampling two peripheral zone sites (where most tumours are likely to be). Two samples are seminal vesicle and four are from the transition zone. No anterior samples are taken. Our method samples the anterior zone and provides six biopsies from different areas in the peripheral zone and two from the transition zone. Seminal vesicle sampling is not undertaken in our method as patients with seminal vesicle invasion are usually identified on imaging and not offered surgery.

This method represents a modification of a technique previously reported by one of the co-authors (AYW) in which fresh tissue was removed from a single slice from 150 radical prostatectomy specimens, using a systematic punch sampling method, with a 76% success rate for obtaining tumour tissue. This yielded high-quality DNA and RNA extractions for genomic studies, validating this methodology for fresh tissue was removed from a single slice from 150 radical prostatectomy specimens, using a systematic punch sampling method, with a 76% success rate for obtaining tumour tissue.

In conclusion, we describe a systematic, rapid method of sampling for fresh radical prostatectomy specimens designed specifically to meet the needs of current research into prostatic carcinoma in that tissue is biobanked from the anterior, peripheral and transition zones with morphological confirmation not just of the nature of the tissue (benign/malignant), but also of Gleason grade and tumour stage. The protocol is logical, systematic and requires no specialised equipment.

Extraprostatic extension and margin positivity (among other factors) determine if patients enter trials or receive adjuvant therapy after surgery. The method described in this paper does not compromise assessment of either of these as the capsule is avoided during sampling and the margins remain intact with almost all of the prostate being submitted for routine histological analysis. Methods describing stripping of the capsule, such as that described by Bova et al., would not meet the current requirements of the RCPath dataset.

Methods involving removal of large amounts of tissue for research also compromise routine reporting. The method recently described by Morrison et al. takes every other slice for research. The RCPath dataset states that it is preferable to embed the entire prostate as in a study of 1383 patients, those with negative margins using step sectioning of the entire specimen had a lower risk of progression than patients whose specimens were partially sampled. In the Morrison et al. method, although the entire capsule is examined for diagnosis, it is obtained by being stripped from the rest of the slice, which is harvested for research tissue (and divided into quadrants) hampering assessment of extraprostatic extension. The authors also state in their paper that the method is time consuming.

Bertlisonn et al. describe a method where a whole slice of prostate is taken intact for research. This technique requires a specialised plastic rack and cryoclamp to cut and freeze the slice. Specimens are removed from the slice with a drilling device. The slice is not available for diagnosis, but it is only taken at 2 mm thickness. To locate the tumour for research, tissue from adjacent parafin blocks is examined and matched to the frozen slice by transposing an image. The major barrier to widespread use of this protocol is the equipment required and labour-intensive method to identify and obtain samples of tumour, compared to our method in which after routine histological reporting, the likely nature of the banked samples is known.

In comparison with other described methods, the method described here compares favourably on the number of cases in which tumour has been successfully sampled at 88%. Others who used methods which were not reliant on visualisation of the tumour for sampling quoted rates of 75% and 72%. Lower positive rates were quoted by those using methods in which the tumour needed to be macroscopically evident, for example, 57% and 65%. In conclusion, we describe a systematic, rapid method of fresh tissue sampling which balances the need for accurate routine histopathological reporting with the need to provide good-quality fresh samples for research that are able to supply quickly the detailed morphological information necessary to meet the needs of researchers.
Take-home messages

► Newly emerging research into prostate cancer requires increasingly complex information about samples such as zone of origin, Gleason grade and stage whilst not compromising histological reporting to the standards set by the Royal College of Pathologists.

► This article reviews previously described methods of fresh tissue sampling from radical prostatectomy specimens for research and describes a method used in Oxford which is simple, logical and cost effective.

► The method of fresh radical prostatectomy sampling described in this article involves punch biopsies sampled from a slice approximately 8mm superior to the apex.

Acknowledgements Professor Lars Egevad, Karolinska Institute, Stockholm, Sweden (with whom we are in a long established research collaboration with), for ongoing help with our methods of radical prostatectomy sampling for research.

We acknowledge the contribution to this study made by the Oxford Centre for Histopathology Research and the Oxford Radcliffe Biobank, which are supported by the NIHR Oxford Biomedical Research Centre.

Contributors All of the authors of this paper (PSG, ISDR, LB, RP, AYW, FCH, CV) were involved in design and conception of the method and drafting and reviewing the manuscript. All approved the final manuscript. There is no one else who should have been included as an author who has been omitted.

Funding The NIHR Biomedical Research Centre (BRC), Oxford funds research time for PG, LB and CV.

Competing interests None.

Ethics approval NRES.

Provenance and peer review Commissioned; internally peer reviewed.

REFERENCES
